A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 48
- Registration Number
- NCT06761898
- Locations
- 🇺🇸
Fortrea Cru, Daytone Beach, Daytona Beach, Florida, United States
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Conditions
- Hormone-receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 92
- Registration Number
- NCT06756932
- Locations
- 🇺🇸
Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Conditions
- Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 218
- Registration Number
- NCT06257264
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇺🇸Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast CancerBreast CancerMetastatic Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 33
- Registration Number
- NCT06253195
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorHormone Receptor Positive Malignant Neoplasm of BreastAdvanced Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNon-small Cell Lung CancerHormone Receptor Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 79
- Registration Number
- NCT06120283
- Locations
- 🇧🇷
Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Brazil
🇧🇷Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Brazil
🇺🇸Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.